Does hepatocyte growth factor/c-Met signal play synergetic role in lung cancer?

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 4, 2010, Pages 833-839

  Wang, Xiangdong ^a   Li, Ka ^a   Chen, Hong ^a   Wang, Diane ^a   Zhang, Yong ^a   Bai, Chunxue ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

C Met; Epidermal growth factor receptor; Hepatocyte growth factor; Lung cancer; Therapy

Indexed keywords

MATRIX METALLOPROTEINASE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; VASCULOTROPIN A;

ANIMAL; ARTICLE; BIOSYNTHESIS; ENZYMOLOGY; HUMAN; LUNG TUMOR; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; HEPATOCYTE GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASES; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953923855     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01040.x     Document Type: Article

References (42)

1. Stamos J, Lazarus RA, Yao X. Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor. EMBO J. 2004, 23:2325-35.
2. Nakamura T. Structure and function of hepatocyte growth factor. Prog Growth Factor Res. 1991, 3:67-85.
3. Okuda K, Sasaki H, Yukiue H. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci. 2008, 99:2280-5.
4. Levina V, Marrangoni AM, DeMarco R. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 2008, 3:1-16.
5. Ma PC, Tretiakova MS, MacKinnon AC. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 2008, 47:1025-37.
6. Kishi Y, Kuba K, Nakamura T. Systemic NK4 gene therapy inhibits tumor growth and metastasis of melanoma and lung carcinoma in syngeneic mouse tumor models. Cancer Sci. 2009, 100:1351-8.
7. Buhles A, Collins SA, van Pijkeren JP. Anti-metastatic effects of viral and non-viral mediated Nk4 delivery to tumours. Genet Vaccines Ther. 2009, 7:1-6.
8. To CT, Tsao MS. The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (Review). Oncol Rep. 1998, 5:1013-24.
9. Birchmeier C, Birchmeier W, Gherardi E. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003, 4:915-25.
10. Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be MET? Trends Mol Med. 2005, 11:284-92.
11. Eder JP, Vande Woude GF, Boerner SA. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 2009, 15:2207-14.
12. Stabile LP, Rothstein ME, Keohavong P. Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Mol Cancer Ther. 2008, 7:1913-22.
13. Yang Y, Wislez M, Fujimoto N. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther. 2008, 7:952-60.
14. Chiang YY. Hepatocyte growth factor induces hypoxia-related interleukin-8 expression in lung adenocarcinoma cells. Mol Carcinog. 2009, 48:662-70.
15. Wu Y, Li YY, Matsushima K. CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process. J Immunol. 2008, 181:6384-93.
16. Saucier C, Khoury H, Lai KM. The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. Proc Natl Acad Sci USA. 2004, 101:2345-50.
17. Herynk MH, Zhang J, Parikh NU. Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells. J Exp Ther Oncol. 2007, 6:205-17.
18. Tomita N, Morishita R, Taniyama Y. Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1. Circulation. 2003, 107:1411-7.
19. Bredin CG, Liu Z, Klominek J. Growth factor-enhanced expression and activity of matrix metalloproteases in human non-small cell lung cancer cell lines. Anticancer Res. 2003, 23:4877-84.
20. Jalili A, Shirvaikar N, Marquez-Curtis LA. The HGF/c-Met axis synergizes with G-CSF in the mobilization of hematopoietic stem/progenitor cells. Stem Cells Dev. 2009
21. Catizone A, Ricci G, Galdieri M. Hepatocyte growth factor modulates Sertoli-Sertoli tight junction dynamics. J Cell Physiol. 2008, 216:253-60.
22. Catizone A, Ricci G, Tufano MA. Hepatocyte growth factor (HGF) modulates Leydig cells extracellular matrix components. J Androl. 2009, 10.2164/jandrol.109.007658, DOI
23. Wright TG, Singh VK, Li JJ. Increased production and secretion of HGF alpha-chain and an antagonistic HGF fragment in a human breast cancer progression model. Int J Cancer. 2009, 125:1004-15.
24. Mizuno S, Matsumoto K, Li MY. HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB J. 2005, 19:580-2.
25. Nakamura Y, Matsubara D, Goto A. Constitutive activation of c-Met is correlated with c-Met overexpression and dependent on cell-matrix adhesion in lung adenocarcinoma cell lines. Cancer Sci. 2008, 99:14-22.
26. Jo M, Stolz DB, Esplen JE. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem. 2000, 275:8806-11.
27. Reznik TE, Sang Y, Ma Y. Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res. 2008, 6:139-50.
28. Bonine-Summers AR, Aakre ME, Brown KA. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol Ther. 2007, 6:561-70.
29. Spix JK, Chay EY, Block ER. Hepatocyte growth factor induces epithelial cell motility through transactivation of the epidermal growth factor receptor. Exp Cell Res. 2007, 313:3319-25.
30. Lirdprapamongkol K, Kramb JP, Suthiphongchai T. Vanillin suppresses metastatic potential of human cancer cells through PI3K inhibition and decreases angiogenesis in vivo. J Agric Food Chem. 2009, 57:3055-63.
31. Yano S, Wang W, Li Q. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008, 68:9479-87.
32. Guo A, Villen J, Kornhauser J. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA. 2008, 105:692-7.
33. Abounader R, Reznik T, Colantuoni C. Regulation of c-Met-dependent gene expression by PTEN. Oncogene. 2004, 23:9173-82.
34. Puri N, Salgia R. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog. 2008, 9:1-8.
35. Engelman JA, Zejnullahu K, Mitsudomi T. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007, 316:1039-43.
36. Bean J, Brennan C, Shih JY. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA. 2007, 104:20932-7.
37. Tang Z, Du R, Jiang S. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer. 2008, 99:911-22.
38. Onitsuka T, Uramoto H, Nose N. Acquired resistance to gefitinib: THE contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer. 2009, 10.1016/j.lungcan.2009.05.022, DOI
39. Niemann HH, Jager V, Butler PJ. Structure of the human receptor tyrosine kinase met in complex with the Listeria invasion protein InlB. Cell. 2007, 130:235-46.
40. Salgia R. Role of c-Met in cancer: emphasis on lung cancer. Semin Oncol 2009, 36:S52-8.
41. Chen JT, Huang CY, Chiang YY. HGF increases cisplatin resistance via down-regulation of AIF in lung cancer cells. Am J Respir Cell Mol Biol. 2008, 38:559-65.
42. Lee WJ, Chen WK, Wang CJ. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol. 2008, 226:178-91.